tumor exosome-loaded dendritic cells

Tumor exosome-loaded dendritic cells are a cell-based immunotherapeutic product in which *dendritic cells (DCs)* are loaded with exosomes derived from tumor cells. The modality leverages the potent antigen-presenting capabilities of dendritic cells combined with tumor-associated antigens (TAAs) packaged in tumor-derived exosomes (TEXs) to elicit robust tumor-specific immune responses. Tumor exosome-loaded dendritic cells present antigens from TEXs via MHC class I and II pathways and express costimulatory molecules (CD80, CD86, ICAM-1, etc.), which stimulates cytotoxic T lymphocyte responses as well as NK cell-mediated antitumor immunity. This strategy aims to induce both T cell-dependent and NK cell-dependent antitumor effects and overcome certain immune escape mechanisms employed by tumors. Clinical and preclinical studies indicate potential use in several solid tumors, with evidence for increased T cell infiltration, memory response, and improved survival in animal models. The primary indication is cancer immunotherapy, particularly for solid tumors such as melanoma, lung cancer, gastric cancer, and glioblastoma. Ongoing research and early-phase clinical trials support their safety and immunogenicity, but the approach is not yet broadly approved for standard clinical use[4][5][3][1][6].

Other names

dendritic cells loaded with tumor-derived exosomesDCs loaded with TEXsDC-TEXTEX-DC vaccine